10x Genomics, Inc 8-K, filed Jul 14, 2022
10x Genomics, Inc. (TXG)
8-K
2022-07-14
For: 2022-07-12
View Original
Added on
April 11, 2026
About this 8-K
10x Genomics, Inc filed this 8-K on July 14, 2022, reporting on events of July 12, 2022.
Items reported
- Item 2.02: Financial results
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________
FORM 8-K
______________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 12, 2022

(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
(925 ) 401-7300
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
___________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On July 14, 2022, 10x Genomics, Inc. (the “Company”) issued a press release announcing the Company’s preliminary second quarter revenue for the period ended June 30, 2022. A copy of the press release is attached hereto as Exhibit 99.1.
The information furnished pursuant to Item 2.02 in this Current Report on Form 8-K and the press release attached as Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 8.01 Other Events.
On July 12, 2022, the Company hired James Wilbur, Ph.D., as Chief Commercial Officer of the Company, effective July 27, 2022.
On July 14, 2022, the Company issued a press release announcing Dr. Wilbur's hiring as Chief Commercial Officer. A copy of such press release is attached hereto as Exhibit 99.2 and incorporated herein by reference.
As previously disclosed, the Company's outgoing Chief Commercial Officer, Brad Crutchfield, will continue to provide transition services to the Company through December 31, 2022 unless Mr. Crutchfield's employment is terminated prior to such time.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits.
Exhibit No. | Description of Exhibits | ||||||||||
| 99.1 | |||||||||||
| 99.2 | |||||||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | ||||||||||
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
10x Genomics, Inc. | ||||||||
By: | /s/ Eric S. Whitaker | |||||||
Name: | Eric S. Whitaker | |||||||
Title: | Chief Legal Officer | |||||||
| Date: July 14, 2022 | ||||||||
Exhibit 99.1

10x Genomics Announces Preliminary Second Quarter 2022 Revenue
PLEASANTON, Calif., July 14, 2022 — 10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced that its preliminary revenue is expected to be approximately $114.5 million for the second quarter ended June 30, 2022. This represents an approximate 1% decrease from $115.8 million for the prior year period, and flat revenue sequentially.
Preliminary geographic revenue for the second quarter is expected to be as follows:
•Americas revenue of approximately $70.9 million, an 8% increase over the prior year period and a 19% increase sequentially
•EMEA revenue of approximately $25.6 million, an 11% decrease over the prior year period and a 25% increase sequentially
•APAC revenue of approximately $18.1 million, a 15% decrease over the prior year period and a 47% decrease sequentially
"Our second quarter results fell short of our expectations," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "We continue to have strong confidence in our longer-term opportunity, technology leadership and the underlying strength of our markets. We are more excited than ever to deliver on the full potential of single cell and spatial biology."
In a separate press release issued this afternoon, the company announced the hiring of Jim Wilbur, Ph.D. as Chief Commercial Officer, effective July 27.
Preliminary Revenue Subject to Adjustment
The preliminary revenue for the three months ended June 30, 2022 included in this release is preliminary and prior to the completion of the company’s financial statement close process and related internal control over financial reporting, and is therefore subject to adjustment. Management will provide additional information in conjunction with the release of its full second quarter 2022 financial results scheduled on August 8, 2022.
2022 Guidance and Financial Outlook
10x Genomics will discuss its full year 2022 guidance when it reports its full financial results for second quarter 2022 in connection with its earnings call on Monday, August 8.
Webcast and Conference Call Information
Company management will host a conference call Monday, August 8 beginning at 1:30 PM Pacific Time / 4:30 PM Eastern Time to discuss results and its financial guidance. Live audio of the webcast will be available at http://investors.10xgenomics.com. The webcast will be archived and available for replay at least 45 days after the event.
About 10x Genomics
10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human health. Our integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. 10x Genomics products have been adopted by researchers around the world including in all of the top 100 global research institutions as ranked by Nature in 2020 based on publications and all of the top 20 global pharmaceutical companies by 2020 research and development spend and have been cited in over 3,800 research papers on discoveries ranging from oncology to immunology and neuroscience. Our patent portfolio comprises more than 1,500 issued patents and patent applications.
1

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project" "contemplate," "believe," "estimate," "predict," "potential" or "continue" or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.'s expectations regarding our second quarter preliminary revenue, our business operations, financial performance and results of operations, the opportunities for single cell and spatial methods and our belief with regard to our near and long term opportunities. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management, and actual outcomes and results could differ materially from these statements due to a number of factors. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time.
Although 10x Genomics, Inc. believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. These forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments 10x Genomics may make. Further, as the COVID-19 pandemic is continuously evolving, such forward-looking statements may not accurately or fully reflect the potential impact that the COVID-19 pandemic may have on the business, financial condition, results of operations and cash flows of 10x Genomics, Inc. The forward-looking statements in this press release are based on information available to 10x Genomics, Inc. as of the date hereof, and 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in our expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release.
Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, its website (www.10xgenomics.com), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
2
Exhibit 99.2

10x Genomics Names Jim Wilbur as Chief Commercial Officer
PLEASANTON, Calif., July 14, 2022 — Following a comprehensive search process, 10x Genomics, Inc. (Nasdaq: TXG), today announced the hiring of Jim Wilbur, Ph.D., as Chief Commercial Officer, effective July 27. In this role, Wilbur will be responsible for driving commercial strategy and execution and leading the company’s sales, support and marketing functions.
A life sciences entrepreneur and seasoned global commercial executive, Wilbur brings nearly 30 years of experience building businesses, developing high-performance teams and scaling commercial organizations to drive growth and customer success.
“Jim’s deep experience driving commercial excellence and execution at scale make him the ideal person to lead our global commercial team in this next phase of growth,” said Serge Saxonov, Co-founder and CEO of 10x Genomics. “What stood out from all the other great candidates is Jim’s detailed understanding and passion of the sales craft, his ability to operate strategically from first principles and his technical depth as a top-notch scientist. It’s an incredibly rare combination. He is a great fit with the 10x mission and culture, is rigorous about process and data and has tremendous energy to get things done. We’re thrilled to welcome him to the team.”
Wilbur joins 10x Genomics from Meso Scale Discovery (MSD), the world’s leading provider of highly sensitive multiplex immunoassays. Widely recognized for its innovative and robust technology, MSD develops, manufactures and markets instruments and assays for research use in life sciences and biodefense.
As part of the original team that started the operations of MSD, Wilbur initially led the development of the company’s core technology and products. When MSD launched its first products in 2001, Wilbur assumed leadership for the company’s commercial function, building the global team responsible for marketing, selling and servicing the company’s portfolio of instruments and consumables. Since that time, Wilbur has scaled MSD’s global commercial organization to deliver sustained high growth and cultivate deep partnerships with customers.
“It’s an exciting time to join the 10x team, be part of the company’s mission and have the opportunity to make a difference in a transformational way,” said Wilbur. “10x has a great foundation to build on, and I have strong confidence in the company’s long-term opportunity and ability to fulfill the tremendous promise of single cell and spatial biology. I look forward to helping the team drive a strong culture of commercial excellence, deliver meaningful value for customers and accelerate growth and impact.”
Wilbur earned his bachelor’s degree in chemistry and intellectual history from the University of California, San Diego, and holds his Ph.D. in chemistry from Stanford University. Prior to MSD, he completed an NIH Postdoctoral Fellowship at Harvard University.
About 10x Genomics
10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human health. Our integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. 10x Genomics products have been adopted by researchers around the world including in all of the top 100 global research institutions as ranked by Nature in 2020 based on publications and all of the top 20 global pharmaceutical companies by 2020 research and development spend and have been cited in over 3,800 research papers on discoveries ranging from oncology to immunology and neuroscience. Our patent portfolio comprises more than 1,500 issued patents and patent applications.
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com